Fencabtagene Autoleucel

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes that are genetically engineered with a T cell Antigen Coupler (TAC), comprising of a domain that targets the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2) and another domain that binds to the endogenous T cell receptor (TCR), with potential immunostimulating and antineoplastic activities. Upon administration, fencabtagene autoleucel targets and binds to HER2-expressing tumor cells and activates TCR-mediated signaling pathways, leading to T cell-mediated killing of HER2-expressing tumor cells. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by a variety of cancers.

**Synonyms:** - Autologous Anti-HER2 T-cell Antigen Coupler-expressing T Cells TAC01-HER2 - Autologous Anti-HER2 TAC T Cells TAC01-HER2 - FENCABTAGENE AUTOLEUCEL - TAC 01-HER2 - TAC-01-HER2 - TAC-engineered T Cells TAC01-HER2 - TAC01-HER2